

September 18, 2014
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer

Notice Concerning Relocation of Head Office

SymBio Pharmaceuticals Limited (“the Company”) announces that at a Board of Directors’ meeting held today, it has decided to relocate the head office as follows:

1. New address of the head office
Toranomon 30 Mori Building, 3-2-2 Toranomon, Minato-ku, Tokyo
2. Scheduled date of commencing business at the new office
November 4, 2014 (Tuesday)
3. Purpose of relocation
By integrating office floors, the Company can improve operational efficiency and communication and enhance its business continuity plan (BCP) and security.
4. Impact on business performance and other
 - No change in the financial forecast for the current fiscal year or the mid-term management plan.
 - No need to revise the Articles of Incorporation since it already prescribes that the location of the head office shall be in Minato-ku, Tokyo.

[Contact]
Investor Relations
Tel: +81(0)3 5472 1125